{"id":"NCT02599402","sponsor":"Bristol-Myers Squibb","briefTitle":"Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma","officialTitle":"Clinical Trial of Nivolumab (BMS-936558) Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma CheckMate 401: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 401","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-20","primaryCompletion":"2020-02-10","completion":"2020-02-10","firstPosted":"2015-11-06","resultsPosted":"2021-06-15","lastUpdate":"2021-06-15"},"enrollment":533,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"DRUG","name":"Nivolumab","otherNames":[]},{"type":"DRUG","name":"Ipilimumab","otherNames":[]}],"arms":[{"label":"Combination therapy: Nivolumab + Ipilimumab","type":"EXPERIMENTAL"},{"label":"Monotherapy: Nivolumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the effects of combination treatment of Nivolumab with Ipilimumab followed by Nivolumab monotherapy in patients with previously untreated advanced Melanoma.","primaryOutcome":{"measure":"Incidence of Participants With High-Grade (CTCAE v4.0 Grade 3-5) Treatment-Related Select Adverse Events","timeFrame":"From first dose to 30 days after last dose (up to approximately 37 months)","effectByArm":[{"arm":"Nivolumab + Ipilimumab Total","deltaMin":7,"sd":null},{"arm":"Nivolumab + Ipilimumab ECOG PS0-1","deltaMin":7,"sd":null},{"arm":"Nivolumab + Ipilimumab ECOG PS2","deltaMin":0,"sd":null},{"arm":"Nivolumab + Ipilimumab Brain Metastasis","deltaMin":0,"sd":null},{"arm":"Nivolumab + Ipilimumab Mucosal","deltaMin":0,"sd":null},{"arm":"Nivolumab + Ipilimumab Ocular/Uveal","deltaMin":1,"sd":null},{"arm":"Nivolumab + Ipilimumab Cutaneous","deltaMin":6,"sd":null},{"arm":"Nivolumab + Ipilimumab Acral","deltaMin":0,"sd":null},{"arm":"Nivolumab + Ipilimumab Other","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":111,"countries":["Australia","Austria","Belgium","Finland","France","Germany","Ireland","Italy","Norway","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["37307514"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":356,"n":533},"commonTop":["Diarrhoea","Fatigue","Nausea","Pruritus","Pyrexia"]}}